Spinal Fusion Drug Pipeline Analysis Report 2024

Around 20% of the United States population is expected to be over 65 by 2030. With the rising aging population, the incidence of spinal fusion procedures is expected to increase in the coming years. Moreover, spinal injuries are a leading cause of spinal fusion procedures. The World Health Organisation reveals that over 15 million  worldwide are living with spinal cord injury (SCI). Hence, researchers are focusing on building a robust portfolio that can be put to use to manage the condition effectively.

Key Takeaway

• Major companies involved in the spinal fusion pipeline drugs market include Tranexamic Acid, Pregabalin and Ketorolac among others.

• Leading drugs currently under pipeline include Exela Pharma Sciences, LLC, Kuros BioSciences B.V., Zimmer Biomet and Novo Nordisk A/S, among others. 

• Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for spinal fusion as they are offering breakthrough designations to manage the condition.

Report Coverage

The Spinal FusionDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into spinal fusiondrugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Spinal Fusion. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The spinal fusion pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from spinal fusion.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to spinal fusion.

Spinal Fusion Drug Pipeline Outlook

Spinal fusion involves the process of joining two or more spinal bones. The connection prevents movement and inhibits pain. During a spinal infusion surgery, a healthcare provider may use bonelike material, metal plates, screws or rods to hold bones together. This allows the bone to fuse and recover. Spinal fusion can help with the symptoms of degenerative disk disease, spinal stenosis, scoliosis, spondylolisthesis and tumor among others.

Drugs and medications are often used to manage pain, and inflammation associated with spinal fusion. In addition, bone growth stimulators and vitamin D supplements are also used to support bone health and expedite healing. Healthcare providers follow a multidisciplinary approach to optimize patient recovery and ensure procedure success. Currently, oxycodone and methocarbamol are commonly used in spinal fusion procedures. While oxycodone is an analgesic, methocarbamol is a skeletal muscle relaxant often prescribed post-operatively. Researchers are working on developing various drugs that help in manage the condition with higher efficacy.

Spinal Fusion – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of spinal fusiondrugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Analgesics

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

• Muscle Relaxants

• Neuropathic Pain Medications

• Bone Growth Stimulating Agents

• Corticosteroids

• Antibiotics

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral

• Parenteral

• Others

Spinal Fusion – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for spinal fusion. There are around 65 drugs in phase IV of spinal fusion drugs.

Spinal Fusion – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under spinal fusionpipeline analysis include analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, neuropathic pain medications, bone growth stimulating agents, corticosteroids, and antibiotics. Each drug class has a specific function and is administered based on patient specifications.

Spinal FusionClinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the spinal fusiondrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in spinal fusion clinical trials:

• Kuros BioSciences B.V.

• Zimmer Biomet

• Novo Nordisk A/S

• Pacira Pharmaceuticals, Inc.

• Exela Pharma Sciences, LLC.

Spinal Fusion– Emerging Drugs Profile 

Ketorolac

Sponsored by the Ascension South East Michigan, low-dose ketorolac is being investigated as an analgesic during the early post-operative period (within 48 hours) of spinal fusion.

Pregabalin

This is a neuropathic pain drug that is being tested to treat multi-modal pain regimen post-spinal surgery. Sponsored by the Hospital for Special Surgery, New York, the drug is currently in phase IV clinical trials.

Tranexamic Acid

Tranexamic acid is being evaluated as an alternative to reduce bleeding in individuals undergoing spinal fusion surgery. Sponsored by Exela Pharma Sciences, LLC, it is in Phase 3 of a multicenter, randomized, double-blind, parallel-group study.

Reasons To Buy This Report

The Spinal Fusion Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for spinal fusion. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within spinal fusion pipeline insights.

Key Questions Answered in the Spinal Fusion– Pipeline Insight Report

• What is the current landscape of spinal fusion pipeline drugs? 
• How many companies are developing spinal fusion drugs? 
• How many phase III and phase IV drugs are currently present in spinal fusion pipeline drugs? 
• Which companies/institutions are leading the spinal fusion drug development? 
• What is the efficacy and safety profile of spinal fusion pipeline drugs? 
• What are the opportunities and challenges present in the spinal fusion drug pipeline landscape? 
• Which company is conducting major trials for spinal fusion drugs? 
• What are the geographies covered for clinical trials in spinal fusion? 
• What are emerging trends in spinal fusion clinical trials?

Related Reports

Spinal Fusion Devices Market

Spinal Cord Injury Market

Spinal Implants and Surgery Devices